IL290141A - Formulations of anti-pvrig antibodies and uses thereof - Google Patents

Formulations of anti-pvrig antibodies and uses thereof

Info

Publication number
IL290141A
IL290141A IL290141A IL29014122A IL290141A IL 290141 A IL290141 A IL 290141A IL 290141 A IL290141 A IL 290141A IL 29014122 A IL29014122 A IL 29014122A IL 290141 A IL290141 A IL 290141A
Authority
IL
Israel
Prior art keywords
formulations
pvrig antibodies
pvrig
antibodies
antibodies formulations
Prior art date
Application number
IL290141A
Other languages
English (en)
Hebrew (he)
Inventor
White Mark
Henry Adewoye Adeboye
Buckley Michael
Lu Jun
Hunter John
Cohen Dayag Anat
Original Assignee
Compugen Ltd
White Mark
Henry Adewoye Adeboye
Buckley Michael
Lu Jun
Hunter John
Cohen Dayag Anat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen Ltd, White Mark, Henry Adewoye Adeboye, Buckley Michael, Lu Jun, Hunter John, Cohen Dayag Anat filed Critical Compugen Ltd
Publication of IL290141A publication Critical patent/IL290141A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL290141A 2019-07-29 2022-01-26 Formulations of anti-pvrig antibodies and uses thereof IL290141A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880021P 2019-07-29 2019-07-29
US201962893051P 2019-08-28 2019-08-28
US201962930206P 2019-11-04 2019-11-04
US202062968660P 2020-01-31 2020-01-31
US202062985702P 2020-03-05 2020-03-05
US202063009367P 2020-04-13 2020-04-13
PCT/US2020/043921 WO2021021837A2 (en) 2019-07-29 2020-07-28 Anti-pvrig antibodies formulations and uses thereof

Publications (1)

Publication Number Publication Date
IL290141A true IL290141A (en) 2022-03-01

Family

ID=72243187

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290141A IL290141A (en) 2019-07-29 2022-01-26 Formulations of anti-pvrig antibodies and uses thereof

Country Status (11)

Country Link
US (1) US20220280643A1 (https=)
EP (1) EP4003417A2 (https=)
JP (1) JP2022542505A (https=)
KR (1) KR20220041881A (https=)
CN (1) CN114615993A (https=)
AU (1) AU2020323926A1 (https=)
BR (1) BR112022001575A2 (https=)
CA (1) CA3149093A1 (https=)
IL (1) IL290141A (https=)
MX (1) MX2022001146A (https=)
WO (1) WO2021021837A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2022069940A1 (en) * 2020-09-30 2022-04-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2022171080A1 (zh) * 2021-02-09 2022-08-18 上海君实生物医药科技股份有限公司 抗cd112r抗体及其用途
EP4403574A4 (en) 2021-09-15 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd PD-1-Specific Protein and Its Pharmaceutical Use
EP4403573A4 (en) * 2021-09-15 2024-12-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY
WO2024027824A1 (zh) * 2022-08-05 2024-02-08 上海君实生物医药科技股份有限公司 抗cd112r抗体药物组合物及其用途
CN120112553A (zh) * 2022-08-10 2025-06-06 广州百济神州生物制药有限公司 抗pvrig抗体和使用方法
CN117957254A (zh) * 2022-08-31 2024-04-30 石药集团巨石生物制药有限公司 抗pvrig抗体及其应用
KR20250156744A (ko) 2023-03-15 2025-11-03 상하이 맙젠 바이오텍 리미티드 Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도
WO2024245388A1 (zh) * 2023-06-01 2024-12-05 信达生物制药(苏州)有限公司 抗pvrig抗体及其应用
TW202502812A (zh) * 2023-06-06 2025-01-16 大陸商上海藥明生物技術有限公司 抗pvrig抗體及其用途
CN120005023B (zh) * 2023-12-22 2025-12-26 华润生物医药有限公司 抗pvrig抗体及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9714A (en) 1853-05-10 Machine fob making hook-headed spikes
US289A (en) 1837-07-19 Cooking-stove
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
DK3653221T5 (da) * 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
US10550173B2 (en) * 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
WO2017165736A1 (en) * 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
IL317989A (en) * 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
CR20190291A (es) * 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
JP2023500651A (ja) * 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
WO2022069940A1 (en) * 2020-09-30 2022-04-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2022165275A2 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
WO2022165266A1 (en) * 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
US12462008B2 (en) 2021-04-23 2025-11-04 Beijing Boe Technology Development Co., Ltd. Unlocking control method and device, electronic apparatus, and computer-readable storage medium
WO2023064958A1 (en) * 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
US20240103010A1 (en) * 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
TW202515608A (zh) * 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Also Published As

Publication number Publication date
BR112022001575A2 (pt) 2022-04-19
WO2021021837A3 (en) 2021-03-11
AU2020323926A1 (en) 2022-03-10
KR20220041881A (ko) 2022-04-01
US20220280643A1 (en) 2022-09-08
MX2022001146A (es) 2022-03-17
EP4003417A2 (en) 2022-06-01
JP2022542505A (ja) 2022-10-04
CA3149093A1 (en) 2021-02-04
WO2021021837A2 (en) 2021-02-04
CN114615993A (zh) 2022-06-10

Similar Documents

Publication Publication Date Title
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL283754A (en) Anti-claudin antibodies, preparations containing them and their uses
SG11202100888WA (en) Anti-avb8 antibodies and compositions and uses thereof
IL289585A (en) DLL3-targeted antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL286100A (en) Formulations of anti-il-36r antibodies
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en) Anti-npr1 antibodies and uses thereof
IL291131A (en) Formulations of anti-il-23p19 antibodies
IL289656A (en) Anti-tigit antibodies and their application
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en) Anti-il-27 antibodies and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
SG11202102875YA (en) Anti-fgfr2 antibody formulations
SG11202104012QA (en) Antibody formulations
IL283890A (en) Anti-periostin antibodies and their uses